Association between treatment and resolution of enthesitis.
| Univariable Model | Multivariable Model | |||
|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |
| Sex, male | 1.61 (0.97-2.68) | 0.07 | 1.66 (0.97-2.84) | 0.06 |
| Baseline age, yrs | 1.00 (0.98-1.02) | 0.85 | 1.00 (0.98-1.02) | 0.98 |
| Baseline PsA duration, yrs | 1.00 (0.98-1.03) | 0.81 | 1.00 (0.97-1.03) | 0.99 |
| Baseline enthesitis count | 0.96 (0.87-1.06) | 0.45 | 0.97 (0.87-1.09) | 0.65 |
| Baseline actively inflamed joint count | 0.98 (0.96-1.00) | 0.03 | 0.97 (0.95-0.99) | 0.01 |
| BMI, kg/m2 | 1.01 (0.97-1.05) | 0.69 | 1.02 (0.97-1.06) | 0.49 |
| Nail lesions | 1.26 (0.76-2.08) | 0.37 | 1.27 (0.75-2.15) | 0.38 |
| Fibromyalgia | 1.01 (0.56-1.82) | 0.97 | 1.31 (0.69-2.47) | 0.41 |
| Medication category | 0.58* | 0.43* | ||
| Category I | Ref | Ref | Ref | Ref |
| Category II | 1.40 (0.74-2.63) | 0.30 | 1.51 (0.78-2.91) | 0.30 |
| Category III | 1.24 (0.67-2.31) | 0.50 | 1.42 (0.74-2.71) | 0.22 |
↵*Global P value. OR: odds ratio; PsA: psoriatic arthritis.